Burning Rock Biotech Files 6-K Report

Ticker: BNR · Form: 6-K · Filed: Aug 23, 2024 · CIK: 1792267

Sentiment: neutral

Topics: reporting, foreign-issuer

TL;DR

Burning Rock Biotech filed a 6-K, standard reporting for foreign issuers.

AI Summary

Burning Rock Biotech Limited filed a Form 6-K on August 23, 2024, incorporating by reference Exhibit 99.1. This filing is for the month of August 2024 and pertains to their status as a foreign private issuer. The company's principal executive offices are located at No.5 Xingdao Ring Road North, International Bio Island, Guangzhou, Guangdong, People's Republic of China.

Why It Matters

This filing indicates ongoing reporting requirements for Burning Rock Biotech as a foreign private issuer, providing updates to investors.

Risk Assessment

Risk Level: low — A Form 6-K is a routine filing for foreign private issuers and does not typically contain material non-public information that would significantly alter risk.

Key Players & Entities

FAQ

What is the purpose of a Form 6-K filing?

A Form 6-K is a report of foreign private issuers pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934, used to furnish information to the SEC that the issuer makes or is required to make public in its home country.

What is the filing date of this Form 6-K?

This Form 6-K was filed on August 23, 2024.

Where are Burning Rock Biotech Limited's principal executive offices located?

The principal executive offices are located at No.5 Xingdao Ring Road North, International Bio Island, Guangzhou, Guangdong, People's Republic of China.

Does Burning Rock Biotech file annual reports under Form 20-F or Form 40-F?

The filing indicates that the registrant files annual reports under Form 20-F.

What exhibit is incorporated by reference in this filing?

Exhibit 99.1 is incorporated by reference, excluding specific paragraphs and tables related to non-GAAP measures.

Filing Stats: 219 words · 1 min read · ~1 pages · Grade level 13.3 · Accepted 2024-08-23 06:06:55

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Burning Rock Biotech Limited By: /s/ Leo Li Name: Leo Li Title: Chief Financial Officer Date: August 23, 2024 4

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing